Bryostatin Treatment of Moderately Severe Alzheimer's Disease
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Neurotrope Bioscience, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04538066
- Locations
- 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Miami Dade Medical Research Institute, Miami, Florida, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Neurotrope Bioscience, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT03560245
- Locations
- 🇺🇸
Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Neuro Pain Medical Center, Fresno, California, United States
🇺🇸Nader Pharmacology Research Institute, Los Alamitos, California, United States
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Neurotrope Bioscience, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT02431468
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸J. Gary Booker, MD APMC Clinical Drug Trials, Shreveport, Louisiana, United States
🇺🇸University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States
Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Neurotrope Bioscience, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02221947
- Locations
- 🇺🇸
California Clinical Trials Medical Center, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath